A Phase II Study of MGCD0103 (MG-0103) in Patients With Refractory Chronic Lymphocytic Leukemia

NCT ID: NCT00431873

Last Updated: 2015-07-01

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 21 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2007-01-31
• Study Completion Date: 2008-11-30

Brief Summary

In this study, MGCD0103, a new anticancer drug under investigation, is given three times weekly to patients with refractory chronic lymphocytic leukemia.

Conditions

Lymphocytic Leukemia, Chronic

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

1

MGCD0103 administered orally three times per week.

Group Type: EXPERIMENTAL

MGCD0103

Intervention Type: DRUG

MGCD0103 Administered orally three times per week.

Interventions

MGCD0103

MGCD0103 Administered orally three times per week.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Pathologic confirmation of CLL.
• Prior Treatment. There will be no limit to prior therapy. Therapy with fludarabine and Rituxan must have failed (disease progression, intolerance, or not a candidate).
• Age 18 years or greater.
• ECOG performance status of 0 or 1.
• Laboratory requirements (must be done within 7 days prior to study initiation):

• Total Bilirubin ≤ 1.5 x Upper Limit of Normal (ULN).
• Aspartate transaminase (AST/SGOT) and Alanine transaminase (ALT/SGPT) ≤ 2.5 x ULN.
• Serum Creatinine ≤1 .5 x ULN.
• Patients or their legal representative must be able to read, understand, and sign a written informed consent (approved by the institutional review board/Ethics Committee (IRB/EC)) within 14 days prior to start of treatment.

Exclusion Criteria

• Patients with another active cancer (excluding basal cell carcinoma or cervical intraepithelial neoplasia (CIN/cervical in situ) or melanoma in situ). Prior history of cancer is allowed, as long as there is no active disease.
• Pregnant or lactating women. Women of child-bearing potential (WOCBP) must have a negative serum pregnancy test documented within 7 days prior start of study drug.
• WOCBP and men whose partners are WOCBP must use an acceptable method of contraception while enrolled on this study, and for a period of 3 months following study drug treatment. Patients unwilling or unable to follow this guideline will be excluded. An example of an acceptable form of contraception is a double barrier method, such as condom with diaphragm.
• Patients with uncontrolled intercurrent illness, active or uncontrolled infections, or a fever > 38.5ºC (not due to tumor fever) on the day of scheduled dosing.
• Patients with serious illnesses, medical conditions, or other medical history, including laboratory results, which, in the investigator's opinion, would be likely to interfere with a patient's participation in the study, or with the interpretation of the results.
• Patients who have been treated with any investigational drug within 28 days prior to study initiation (an investigational drug is one for which there is no approved indication), or who are receiving concurrent treatment with other experimental drugs or anti-cancer therapy. Patients must have recovered from all transient toxicity induced by prior therapy.
• Known hypersensitivity to HDAC inhibitors, to any of the components of MG-0103 (refer to IB). Patients who have known anaphylaxis or IgE-mediated hypersensitivity to murine proteins or to any component of rituximab will not be allowed to receive rituximab concomitantly on this study.
• Known human immunodeficiency virus (HIV) or known active Hepatitis B or C. Testing is not required for patients not suspected of having these conditions. For patients with a history of Hepatitis B or C that is no longer active, the Investigator should contact MethylGene in advance to confirm patient's eligibility.
• Any condition (e.g., known or suspected poor compliance, psychological instability, geographical location, etc) that, in the judgment of the investigator, may affect the patient's ability to sign the informed consent and undergo study procedures.
• Any condition that will put the patient at undue risk or discomfort as a result of adherence to study procedures. For example, consider requirement to take MG-0103 with a low-pH drink and recommendation to avoid agents that increase gastric-pH.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Mirati Therapeutics Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Gregory Reid, MSc, MBA

Role: STUDY_DIRECTOR

MethylGene Inc.

Locations

Veteran Affairs Medical Center Research Service

Kansas City, Missouri, United States

Memorial Sloan-Kettering Cancer Center

New York, New York, United States

Gabrail Cancer Center

Canton, Ohio, United States

Cleveland Clinic/Chronic Leukemia/Multiple Myeloma Program

Cleveland, Ohio, United States

Ohio State University, James Cancer Hospital

Colombus, Ohio, United States

MD Anderson Cancer Center

Houston, Texas, United States

Queen Elizabeth II Health Sciences Centre

Halifax, Nova Scotia, Canada

McMaster University Health Center

Hamilton, Ontario, Canada

Ottawa Hospital - General Campus

Ottawa, Ontario, Canada

UHN - Princess Margaret Hospital

Toronto, Ontario, Canada

Hopital Charles-LeMoyne

Greenfield Park, Quebec, Canada

Hopital Maisonneuve-Rosemont

Montreal, Quebec, Canada

CHA, Hopital Enfant-Jesus

Québec, Quebec, Canada

Countries

United States; Canada

Other Identifiers

0103-009

Identifier Type: -

Identifier Source: org_study_id